Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
Public ClinicalTrials.gov record NCT04999839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Multicenter, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Moderate to Severe Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI-034858 and explore the immune response to NDI-034858 in participants with moderate to severe plaque psoriasis.
Study identification
- NCT ID
- NCT04999839
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 259 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 11, 2021 (Actual)
- Primary completion
- Aug 19, 2022 (Actual)
- Completion
- Sep 12, 2022 (Actual)
- Last update posted
- Sep 28, 2023
2021 – 2022
United States locations
- U.S. sites
- 59
- U.S. states
- 24
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nimbus site 137 | Birmingham | Alabama | 35205 | — |
| Nimbus site 156 | Birmingham | Alabama | 35244 | — |
| Nimbus site 132 | Scottsdale | Arizona | 85255 | — |
| Nimbus site 133 | Bryant | Arkansas | 72022 | — |
| Nimbus site 134 | Fountain Valley | California | 92708 | — |
| Nimbus site 108 | Los Angeles | California | 90033 | — |
| Nimbus site 124 | Sacramento | California | 95816 | — |
| Nimbus site 153 | San Diego | California | 92122 | — |
| Nimbus site 111 | San Diego | California | 92123 | — |
| Nimbus site 148 | Santa Rosa | California | 95405 | — |
| Nimbus site 120 | Sherman Oaks | California | 91403 | — |
| Nimbus site 155 | Doral | Florida | 33122 | — |
| Nimbus site 149 | Hialeah | Florida | 33012 | — |
| Nimbus site 130 | Largo | Florida | 33770 | — |
| Nimbus site 160 | Margate | Florida | 33063 | — |
| Nimbus site 107 | Miami Lakes | Florida | 33014 | — |
| Nimbus site 139 | Miami Lakes | Florida | 33014 | — |
| Nimbus site 118 | Ocala | Florida | 34470 | — |
| Nimbus site 157 | Sweetwater | Florida | 33172 | — |
| Nimbus site 101 | Tampa | Florida | 33607 | — |
| Nimbus site 102 | Tampa | Florida | 33613 | — |
| Nimbus site 116 | West Palm Beach | Florida | 33406 | — |
| Nimbus site 147 | Columbus | Georgia | 31904 | — |
| Nimbus site 150 | Macon | Georgia | 31217 | — |
| Nimbus site 119 | Sandy Springs | Georgia | 30328 | — |
| Nimbus site 123 | Skokie | Illinois | 60077 | — |
| Nimbus site 159 | Clarksville | Indiana | 47129 | — |
| Nimbus site 140 | Indianapolis | Indiana | 46250 | — |
| Nimbus site 154 | Overland Park | Kansas | 66210 | — |
| Nimbus site 161 | Louisville | Kentucky | 40217 | — |
| Nimbus site 105 | Louisville | Kentucky | 40241 | — |
| Nimbus site 136 | Lake Charles | Louisiana | 70605 | — |
| Numbus site 114 | Metairie | Louisiana | 70006 | — |
| Nimbus site 122 | Rockville | Maryland | 20850 | — |
| Nimbus site 115 | Beverly | Massachusetts | 01915 | — |
| Nimbus site 135 | Quincy | Massachusetts | 02169 | — |
| Nimbus site 146 | Ann Arbor | Michigan | 48103 | — |
| Nimbus site 103 | Bay City | Michigan | 48706 | — |
| Nimbus site 112 | Troy | Michigan | 48084 | — |
| Nimbus site 138 | Troy | Michigan | 48084 | — |
| Nimbus site 158 | New Brighton | Minnesota | 55112 | — |
| Nimbus site 143 | New York | New York | 10075 | — |
| Nimbus site 129 | Charlotte | North Carolina | 28277 | — |
| Nimbus site 106 | Wilmington | North Carolina | 28405 | — |
| Nimbus site 127 | Bexley | Ohio | 43209 | — |
| Nimbus site 145 | Columbus | Ohio | 43213 | — |
| Nimbus site 128 | Fairborn | Ohio | 45324 | — |
| Nimbus site 141 | Norman | Oklahoma | 73071 | — |
| Nimbus site 125 | Pittsburgh | Pennsylvania | 15123 | — |
| Nimbus site 110 | Charleston | South Carolina | 29407 | — |
| Nimbus site 117 | Jackson | Tennessee | 38305 | — |
| Nimbus site 121 | Nashville | Tennessee | 37215 | — |
| Nimbus site 109 | Arlington | Texas | 76011 | — |
| Nimbus site 113 | Bellaire | Texas | 77401 | — |
| Nimbus site 131 | Katy | Texas | 77494 | — |
| Nimbus site 104 | San Antonio | Texas | 78213 | — |
| Nimbus site 152 | San Antonio | Texas | 78229 | — |
| Nimbus site 162 | Webster | Texas | 77598 | — |
| Nimbus site 142 | Spokane | Washington | 99026 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04999839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2023 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04999839 live on ClinicalTrials.gov.